Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma

BACKGROUND AND PURPOSE: Combining inhibitors of vascular endothelial growth factor and the programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but the disease-specific and agent-specific mechanisms of benefit remain unclear. We examined the efficacy and defined the...

Descripción completa

Detalles Bibliográficos
Autores principales: Shigeta, Kohei, Matsui, Aya, Kikuchi, Hiroto, Klein, Sebastian, Mamessier, Emilie, Chen, Ivy X, Aoki, Shuichi, Kitahara, Shuji, Inoue, Koetsu, Shigeta, Ayako, Hato, Tai, Ramjiawan, Rakesh R, Staiculescu, Daniel, Zopf, Dieter, Fiebig, Lukas, Hobbs, Gabriela S, Quaas, Alexander, Dima, Simona, Popescu, Irinel, Huang, Peigen, Munn, Lance L, Cobbold, Mark, Goyal, Lipika, Zhu, Andrew X, Jain, Rakesh K, Duda, Dan G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689089/
https://www.ncbi.nlm.nih.gov/pubmed/33234602
http://dx.doi.org/10.1136/jitc-2020-001435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689089/
https://www.ncbi.nlm.nih.gov/pubmed/33234602
http://dx.doi.org/10.1136/jitc-2020-001435

Ejemplares similares